OBIO vs PTN โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
OBIO Captures Institutional Edge (2โ2 Pillars ยท 5โ5 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Orchestra BioMed Holdings, Inc. Ordinary Shares (OBIO) driven by superior Momentum & Technical, Options & Structure while PTN counters with relative strength in Valuation, Growth & Margin. Fundamentally, OBIO trades at N/M Forward P/E with -195.4% operating margin (-89.4% YoY revenue) versus PTN at 42.9x Forward P/E and -65.7% operating margin (-80.1% YoY). In options structure, OBIO sits in BREAKOUT (<1st %ile IV; Dealer Gamma Walls on Pro) against PTN sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | OBIO Revenue | PTN Revenue | OBIO Op. Margin | PTN Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | N/A | $70M | N/A | 38.6% | PTN |
| FY2019 | N/A | $60M | N/A | 59.3% | PTN |
| FY2020 | N/A | $0M | N/A | -20007.6% | PTN |
| FY2022 | $0M | $0M | -924.3% | -2491.6% | OBIO |
| FY2023 | $0M | $0M | -1866.2% | -668.7% | PTN |
| FY2024 | $0M | $0M | -2437.5% | -501.0% | PTN |
| FY2025 | $30M | N/A | -154.7% | N/A | OBIO |
| FY2026 | N/A | $10M | N/A | -65.7% | PTN |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | OBIO | PTN | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $570.6M | $11.1M | Larger Scale | OBIO |
| Trailing P/E Ratio Valuation | N/M | 42.9x | Lower Multiple | PTN |
| Forward P/E Ratio Valuation | N/M | 42.9x | Lower Multiple | PTN |
| Revenue Growth (YoY) Growth | -89.4% | -80.1% | Higher Growth | PTN |
| Operating Margin (TTM) Profitability | -195.4% | -65.7% | Higher Margin | PTN |
| Net Profit Margin Profitability | -182.5% | -63.5% | Higher Margin | PTN |
| Return on Equity (ROE) Capital Efficiency | -182.3% | -877.5% | Higher ROE | OBIO |
| 52-Week Range Position Momentum | 92% ($3โ$7) | 6% ($5โ$31) | Stronger Trend | OBIO |
| Beta / 30D Volatility Risk Regime | 1.15ฮฒ ยท 82% Vol | 0.87ฮฒ ยท 106% Vol | Lower Realized Risk | OBIO |
| Unified Institutional Score Composite Signal | 37.5 / 100 (SELL) | 31.5 / 100 (SELL) | Higher Composite | OBIO |